Hypomethylation‐associated Sox11 upregulation promotes oncogenesis via the PI3K/AKT pathway in OLP‐associated OSCC
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Yi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: SOXC Transcription Factors, Proto-Oncogene Proteins c-akt, DNA Methylation, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Foundation of Chengdu, China, Science and Technology Foundation of Sichuan Province, China.
Abstract (Originalsprache)
Oral lichen planus (OLP) is a particularly prevalent oral disorder with the potential to progress to oral squamous cell carcinoma (OSCC). SRY‐box transcription factor 11 (Sox11) has been reported to serve as a prognostic marker for various cancers. However, the role and mechanism of Sox11 in OLP‐related OSCC are unknown. Our results indicated that Sox11 was highly expressed, and that Sox11 promoter methylation was significantly reduced in OLP‐associated OSCC tissues. High Sox11 expression and Sox11 promoter hypomethylation indicate a poor patient prognosis. According to in vivo and in vitro experiments, the knockdown of Sox11 inhibited proliferation, invasion, and migration while driving its apoptotic death in OSSC cells; Sox11 overexpression exerted the opposite effect as Sox11 knockdown. Mechanistically, knockdown of Sox11 inhibited PI3K/AKT and glycolysis pathway, and overexpression of Sox11 enhanced the PI3K/AKT and glycolysis pathways in OSCC cells. In addition, we demonstrated that Sox11 overexpression accelerated the progression of OSCC, at least in part by promoting PI3K/AKT pathway activation. In conclusion, our data indicated that the DNA hypomethylation‐associated upregulation of Sox11 could promote oncogenic transformation via the PI3K/AKT pathway in OLP‐associated OSCC. Therefore, Sox11 might be a reliable biomarker for predicting the progression of precancerous oral tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stomatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
- Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science…
- Department of Stomatology, Sichuan Provincial People's Hospital Wenjiang Hospital, Chengdu, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Foundation of Chengdu, China
- Science and Technology Foundation of Sichuan Province, China
- Research Fund of Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
Zitieren
APA
Liu, Y., Cao, P., Xiao, L., Tang, N., Fei, W., & Li, X. (2024). Hypomethylation‐associated Sox11 upregulation promotes oncogenesis via the PI3K/AKT pathway in OLP‐associated OSCC. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18556
Vancouver
Liu Y, Cao P, Xiao L, Tang N, Fei W, Li X. Hypomethylation‐associated Sox11 upregulation promotes oncogenesis via the PI3K/AKT pathway in OLP‐associated OSCC. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18556
BibTeX
@article{Liu2024,
author = {Liu, Yi and Cao, Peilin and Xiao, Li and Tang, Na and Fei, Wei and Li, Xue},
title = {Hypomethylation‐associated Sox11 upregulation promotes oncogenesis via the PI3K/AKT pathway in OLP‐associated OSCC},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18556}
}
EUVIMED